A pre-scheduled independent Safety Monitoring Committee (SMC) has recommended that the U.S. Phase 2 COVID-19 study with opaganib continue with no changes; the study is more than 50% enrolled and enrollment is planned to be completed in the coming weeks -- The global Phase 2/3 COVID-19 study with ...
Q2 / 2020 net revenues of approximately $21 million , up from $1.1 million in Q1/2020 and $1.6 million in Q2/2019, an increase of approximately 1,900% and 1,200%, respectively -- Completed acquisition of Movantik ® from AstraZeneca and secured exclusive control over U.S. ...
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered into a binding term sheet with Cosmo Pharmaceuticals N.V. ...
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its second quarter 2020 financial results and business highlights on Thursday, ...
The global Phase 2/3 study with opaganib is set to enroll up to 270 patients with severe COVID-19 across 40 clinical sites -- The global Phase 2/3 study has been approved in Mexico , the UK and Russia and is also under review in Italy, Brazil and additional countries -- Enrollment in a parallel ...
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will participate in the following virtual conferences in August: BTIG Virtual Biotechnology ...
RedHill acquired Movantik ® for opioid induced constipation from AstraZeneca in April 2020 ; Movantik ® generated $96 million in 2019 -- RedHill and Daiichi Sankyo replaced their co-commercialization agreement for Movantik ® with a new royalty-bearing agreement, under which RedHill will maintain ...
RHB-204 is a potential first-line oral treatment for pulmonary nontuberculous mycobacteria (NTM) infections, a rare disease with no FDA-approved first-line therapy -- The pivotal Phase 3 study aims to enroll 125 patients at 50 clinical sites across the U.S. ...
The global Phase 2/3 study will enroll up to 270 patients with severe COVID-19 across 40 clinical sites; The study has been approved in the UK and Russia and is under review in Italy , Brazil and Mexico -- Enrollment in a parallel U.S. Phase 2 study in patients with severe COVID-19 is expected to ...
Publication of the Phase 2 U.S. study data show that RHB-102 (Bekinda ® ) 12mg delivers a clinically meaningful improvement in overall stool consistency response versus placebo in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), meeting the study’s primary endpoint -- In ...
Menu